Zydus Ties Up With Synthon for MS Drug in US
ECONOMY & POLICY

Zydus Ties Up With Synthon for MS Drug in US

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).
The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.
As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.
“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.
The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.
This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Next Story
Infrastructure Urban

Welspun Enterprises Wins 910 MLD Panjrapur WTP Contract

Welspun Enterprises (WEL), the infrastructure and energy arm of Welspun World, has secured a major contract from the Brihanmumbai Municipal Corporation (BMC) to design, build and operate a 910 million litres per day (MLD) Water Treatment Plant (WTP) at Panjrapur, Maharashtra.Valued at approximately Rs 31.45 billion, the project encompasses end-to-end civil, mechanical, electrical and instrumentation works, including the construction of a treated water sump and pumping station. Of the total value, nearly Rs 11.56 billion is allocated to Operations & Maintenance (O&M), with an additional..

Next Story
Infrastructure Energy

Mitsubishi Power Wins Boiler Upgrade Contract for O Mon 1 Plant

Mitsubishi Power, a power solutions brand of Mitsubishi Heavy Industries, (MHI), has been awarded a contract to support the oil-to-natural-gas fuel conversion at the O Mon 1 Thermal Power Plant in Can Tho, southern Vietnam. As the OEM of the plant’s existing boiler, Mitsubishi Power will supply key equipment—including new gas burners—and implement a selective catalytic reduction (SCR) system to reduce NOx emissions and help the plant meet stricter environmental standards.The O Mon 1 facility includes two 330 MW units that commenced operations in 2009 and 2015, with all major equipment or..

Next Story
Equipment

Liebherr’s 10,000th XPower Wheel Loader Joins BERGER’s Fleet

BERGER Rohstoffe GmbH has welcomed the 10,000th Liebherr XPower wheel loader to its operations at the Schlag granite quarry in Passau. The milestone machine, officially handed over at Liebherr’s Bischofshofen plant in May 2025, underscores the long-standing partnership between BERGER, Liebherr, and the Beutlhauser Group. Equipped with Liebherr’s signature power-split travel drive, the new L 580 XPower is already delivering strong results under demanding quarry conditions.At the Schlag quarry, BERGER Rohstoffe processes approximately 200,000 tonnes of Bayerwald granite annually into high-qu..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement